NHGRI logo

Since its creation in 1990, the Ethical, Legal and Social Implications (ELSI) Research Program has funded hundreds of research projects, conferences, and other activities-through grants and contracts. This has resulted in many peer reviewed journal articles, books, newsletters, websites, television and radio programs and educational materials. Many of these products are included in this database (updates are still in progress). However, there are likely to be a number of publications missing, particularly those affiliated with older grants.

Overview

The ELSI Publications and Products Database organizes the publications for all ELSI projects and activities by the last name of the principle investigator (PI). Each entry also includes, and can be searched by:

  • A specific topic - or search term - related to an ELSI issue, (i.e., discrimination, genetic testing or privacy)
  • The name of the author
  • The name of the journal
  • The type of grant (i.e., education, research or conference).
  • The grant number.
  • The name of the principal investigator.

Note: To see ALL publications, click on the Search button below without typing anything into the search fields. (Please be aware that publications with multiple authors may be associated with more than one project and will appear on the comprehensive list for each relevant project.)

Missing publication? Many of these products are included in this database (updates are still in progress). However, there are likely to be a number of publications missing, particularly those affiliated with older grants. If you know of an ELSI funded product that is not currently listed in this database, please submit a request to add it.


Topical Bibliographic Resource on DNA Identification

An annotated listing of  publications and other products from research supported by the ELSI program on issues related to using DNA for identification purposes in a wide range of settings.

  • Overview

    The ELSI Publications and Products Database organizes the publications for all ELSI projects and activities by the last name of the principle investigator (PI). Each entry also includes, and can be searched by:

    • A specific topic - or search term - related to an ELSI issue, (i.e., discrimination, genetic testing or privacy)
    • The name of the author
    • The name of the journal
    • The type of grant (i.e., education, research or conference).
    • The grant number.
    • The name of the principal investigator.

    Note: To see ALL publications, click on the Search button below without typing anything into the search fields. (Please be aware that publications with multiple authors may be associated with more than one project and will appear on the comprehensive list for each relevant project.)

    Missing publication? Many of these products are included in this database (updates are still in progress). However, there are likely to be a number of publications missing, particularly those affiliated with older grants. If you know of an ELSI funded product that is not currently listed in this database, please submit a request to add it.


    Topical Bibliographic Resource on DNA Identification

    An annotated listing of  publications and other products from research supported by the ELSI program on issues related to using DNA for identification purposes in a wide range of settings.

HUGHES-HALBERT, Chanita - Comparing Models of Pre-Test Education for BRCA1 Testing [R01 HG001846]

The project will carry out a multi-institutional randomized trial to evaluate whether the outcomes of BRCA1/2 testing among female mutation carriers are improved by providing a psychosocial telephone counseling (PTC) intervention in addition to standard genetic counseling (SGC). The specific aims are: (1) to evaluate the efficacy of PTC delivered in conjunction with SGC, compared to SGC only; (2) to explore the mechanisms by which the PTC impacts on psychosocial and behavioral outcomes; 3) to identify carriers who are most and least likely to benefit from PTC; and (4) to conduct an economic evaluation of the two counseling strategies. The participants in this randomized trial are 290 female carriers of BRCA1/2 mutations and 290 female noncarriers. A baseline assessment will be conducted prior to the offer of testing to collect data on background variables, moderator variables, and baseline levels of outcome variables. Following in-person pre-test genetic counseling and informed consent, participants will have an opportunity to have BRCA1/2 testing. After providing additional written consent, they will receive their results during an individual in-person session with a genetic counselor. Following disclosure of mutation status, carriers of BRCA1/2 mutations will be assigned randomly to receive either SGC follow-up only or SGC plus PTC. The PTC protocol, adapted from the previous research of the study investigators, will be delivered in 6 sessions over a 3-month period after disclosure. Sessions will include supportive counseling and provide training in coping skills to enhance the outcomes of genetic testing. Follow-up interviews will be conducted at 1-, 4-, 6-, and 12-months post-disclosure to collect data on the following outcomes; comprehension, distress, family communications and functioning, adoption of recommended cancer screening practices, and satisfaction with decisions about prophylactic surgery. If beneficial and cost-effective, the proposed PTC intervention can be disseminated to varied research and clinical settings in which BRCA1/2 testing is offered.

Halbert, C. H. Decisions and outcomes of genetic testing for inherited breast cancer risk. Ann. Oncol. 15 Suppl 1, I35–I39 (2004).

[PubMed]
Journal Article

Manne, S. et al. Associations between relationship support and psychological reactions of participants and partners to BRCA1 and BRCA2 testing in a clinic-based sample. Ann. Behav. Med. 28, 211–25 (2004).

[PubMed]
Journal Article

Lerman, C. et al. Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol. Biomarkers Prev. 8, 361–7 (1999).

[PubMed]
Journal Article

Lerman, C. et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J. Natl. Cancer Inst. 89, 148–57 (1997).

[PubMed]
Journal Article

Lawrence, W. F. et al. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol. Biomarkers Prev. 10, 475–81 (2001).

[PubMed]
Journal Article

Lerman, C., Croyle, R. T., Tercyak, K. P. & Hamann, H. Genetic testing: psychological aspects and implications. J. Consult. Clin. Psychol. 70, 784–97 (2002).

[PubMed]
Journal Article
Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD . Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat, 104 (3):321-9. 2007. [PubMed] Journal Article

Halbert, C. H. et al. Predictors of cognitive appraisals following genetic testing for BRCA1 and BRCA2 mutations. J. Behav. Med. 27, 373–92 (2004).

[PubMed]
Journal Article

Cella D., Hughes C., Peterman A., Chang C.H., Peshkin B.N., Schwartz M.D., Wenzel A., Lemke A., Marcus A., Lerman C. "A Brief Assessment of Concerns Associated with Genetic Testing for Cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) Questionnaire." Health Psychology. (accepted for publication)

[PubMed]
Journal Article

Audrain, J., M.D. Schwartz, C. Lerman et al. "Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: The contributions of personality and appraisal." Annals of Behavioral Medicine. Fall 1998; 19(4): 370-7.

Journal Article

Glanz, K., J. Grove, C. Lerman et al. "Correlates of Intentions to Obtain Genetic Counseling and Colorectal Cancer Gene Testing Among At-Risk Relatives from Three Ethnic Groups." Cancer Epidemiology, Biomarkers & Prevention Special Issue. April 1999; 8(4): 329-336. [Pubmed]

[PubMed]
Journal Article

Lerman, C. "Translational Behavioral Research in Cancer Genetics." Preventive Medicine. 1997; 26: S65-S69.

Journal Article

Tercyak K.P., Streisand R., Peshkin B.N., Lerman C. "Psychosocial impact of predictive testing for illness on children and families: Challenges for a new millennium." Journal of Clinical Psychology in Medical Settings, 2000; 7: 55-68.

Journal Article
. Care and Understanding: A Telephone Counseling Program for Women Who Have a BRCA1 or BRCA2 Gene Alteration. The Cancer Assessment and Risk Evaluation Program Care Kit. 2001. Book Chapter

Croyle R., Lerman C. "Risk communication in genetic testing for cancer susceptibility." Journal of the National Cancer Institute Monographs, 1999; 25: 59-66.

[PubMed]
Journal Article

Tercyak K.P., Lerman C., Peskin B.N., Hughes C., Main D., Isaacs C., Schwartz M.D. "Effects of Coping Style and Test Result on Anxiety among Women Participating in Genetic Counseling and Testing for Breast/Ovarian Cancer Risk." Health Psychology. 2001; 20: 217-222.

Journal Article

Tercyak, K. P. (2009). Introduction to the special issue: psychological aspects of genomics and child health. Journal of Pediatric Psychology, 34(6), 589–95. doi:10.1093/jpepsy/jsn127

[PubMed]
Journal Article

Schwartz, M. D. et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J. Clin. Oncol. 21, 4034–41 (2003).

[PubMed]
Journal Article
DeMarco TA, Peshkin BN, Brogan BM . Across the Spectrum: Case Studies in Genetic Counseling for Breast and Ovarian Cancer. J Genet Couns, 10 (5):379-95. 2001. [Full Text] Journal Article

Tercyak, K. P., Peshkin, B. N., Streisand, R., & Lerman, C. (2001). Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psycho-Oncology, 10(4), 336–46. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11462232

[PubMed]
Journal Article

HUGHES-HALBERT, Chanita - African American Participation in Cancer Genetics Research [R01 HG004346]

Despite significant efforts, African Americans continue to experience excess rates of morbidity and mortality from all forms of cancer relative to individuals from other ethnic and racial groups. Research is now being conducted to the molecular basis of cancer through genetic-based studies and to translate this information into strategies for cancer detection, prevention, and treatment. African American reluctance to participate in cancer genetics research will significantly limit efforts to apply these approaches to address racial disparities in cancer outcomes. To develop effective strategies for recruiting African Americans to participate in cancer genetics research and to enhance decisions about participation in this population, empirical data are needed on attitudes and beliefs that act as barriers and facilitators to participation. Studies are also needed to determine how barriers and facilitators may interact with attributes of the study to influence participation within this population. To address these gaps in our knowledge, the specific aims of this mixed methods study are to (1) identify barriers and facilitators to African American participation in cancer genetics research and to translate this information into a psychometrically sound instrument; (2) evaluate within group variation in barriers and facilitators among African Americans based on sociodemographics, experiences with disease, and cultural beliefs and values; and (3) evaluate the associations between participation intentions and two potential influences that include the attributes of the study and barriers and facilitators. The study will be implemented in three Phases and will include African American men and women ages 18-75. In Phase I, we will use qualitative methods to identify barriers and facilitators to participate in cancer genetics research. Phase II will consist of a cross-sectional survey to evaluate within group variation in participation barriers and facilitators based on sociodemographics, experiences with disease, and cultural beliefs and values. In Phase III, we will conduct a conjoint survey to evaluate the relative influence of participation barriers and facilitators and attributes of the study on willingness to enroll in cancer genetics research. To accomplish these goals, we have assembled a team of highly qualified investigators who are experts in the application of qualitative and quantitative methods to minority recruitment, cancer genetics, psychometrics, survey research, conjoint analysis. This study will provide empirical data that can be used to develop more effective strategies for recruiting African Americans to participate in cancer genetics research that enhance decisions about study participation.

McDonald, J. A. et al. Understanding participation by African Americans in cancer genetics research. J. Natl. Med. Assoc. 104, 324–30 (2012).

[PubMed Central]
Journal Article

Halbert, C. H. et al. Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women’s concerns? J. Clin. Oncol. 29, 4302–6 (2011).

[PubMed Central]
Journal Article

McDonald, J. A. et al. Donation intentions for cancer genetics research among African Americans. Genet. Test. Mol. Biomarkers 16, 252–8 (2012).

[PubMed Central]
Journal Article

HUNT, Linda - Clinicians' Concepts of Racial/Ethnic Differences in the Management of Chronic Illness [R01 HG004710]

Genetic knowledge is becoming increasingly central to the way human health and disease are understood and addressed. In order to advance the translation of medical knowledge into effective practice, it is important to know how genetic knowledge is presently understood by clinicians and patients, and applied in their routine medical encounters. Genetic information is already being translated from the abstracted world of laboratory research to the practical context of clinical practice and everyday life. At the same time, there is great interest in understanding and alleviating the unequal burden of disease affecting certain racial/ethnic populations in the U.S. Research has shown that health disparities are largely attributable to non-genetic factors such as socio-economic status, racial discrimination, inadequate health insurance, and unequal exposure to environmental hazards. Still, many believe that genetic research holds a key to explaining and addressing racial/ethnic health disparities. How clinicians translate genetic knowledge into clinical practice, how they integrate genetic and non-genetic illness understandings, and how patients in turn understand this information has not as yet been carefully studied. Using qualitative research techniques of open-ended interviewing and participant observation, the proposed study will explore how a group of primary care clinicians and their patients understand and interpret the genetic and non-genetic basis of two prominent chronic illnesses which differentially impact racial/ethnic minorities: diabetes and cardiovascular disease. The study will examine their understandings of susceptibility and management of these diseases. Comparative qualitative analysis will be used to generate specific profiles of ways that genetic information is interpreted and applied by these clinicians and their patients. The study will conclude with a national survey of primary care clinicians, designed to test the generalizability of the qualitative findings, and examine any hypotheses emerging from the analysis. Our specific aims are to: 1) Understand how genetic concepts of racial/ethnic difference are interpreted and applied by clinicians serving minority populations. 2) Understand the nature of genetic versus non-genetic factors in clinicians' understandings of the causes and management of these common chronic illnesses, which differentially impact minority populations. 3) Understand patients' interpretations of these concepts and of their own risk, health status and treatment responsibility. 4) Generate knowledge of how emerging genetics science can effectively be presented to clinicians and patients, to promote appropriate interpretation and application of genetic knowledge while avoiding possible misinterpretation and racial/ethnic stereotyping. PUBLIC HEALTH RELEVANCE: As genetics becomes increasingly central to medical care, there is a clear need for better understanding of how clinicians translate genetic knowledge into their practice, and how patients in turn understand genetic information. This is especially important in assuring appropriate interpretation and application of genetic knowledge concerning diseases that disproportionately affect racial/ethnic minority populations. This project will be contribute valuable insight into clinician and patient use of genetics concepts in everyday clinical encounters, which will yield better understanding of how emerging genetics knowledge can effectively be presented to clinicians and patients, while avoiding possible misinterpretation and racial/ethnic stereotyping.

Hunt, L. M., Truesdell, N. D. & Kreiner, M. J. Genes, Race, and Culture in Clinical Care: Racial Profiling in the Management of Chronic Illness. Med. Anthropol. Q. (2013). doi:10.1111/maq.12026

[PubMed]
Journal Article

Hunt, L. M., Kreiner, M. & Brody, H. The changing face of chronic illness management in primary care: a qualitative study of underlying influences and unintended outcomes. Ann. Fam. Med. 10, 452–60 (2012).

[Annals of Family Medicine]
Journal Article

Hunt, L. M. & Kreiner, M. J. Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling. Cult. Med. Psychiatry 37, 226–35 (2013).

[PubMed]
Journal Article

IONNO, Sandra - SPUSA 1999 International Conference Genetic Portions [R13 HG001962]

Student Pugwash USA (SPUSA) will hold an international conference, 'Science and Social Responsibility in the New Millennium,' June 28-July 4, 1999. This event, which will bring 200 students, yound professionals, and experts from over 30 countries to the University of California's San Diego campus, will encourage talented young people to explore with senior experts the ethical, legal and social implications of the US Human Genome Project (HGP) and other developments in the field of genetics. One public plenary session will focus on genetics and the HGP and two of the ten working groups at the conference will focus on related issues. One working group will explore genetics in terms of gene therapy, the HGP, cloning, public decision- making, and patenting issues. The second will explore the interplay between computers, biotechnology, taking into consideration the role of computers in accelerating genetics research in the HGP and other initiatives, the impact of genetic databases on research around the world, possible personal freedom issues that arise from these databases, and potential impact of other emerging capabilities. The conference will foster an international network of young people committed to exploring ELSI issues and will initiate a year-long continued investigation into these issues through follow-on activities which will include: on-line discussion groups; local, campus- based activities; media outreach; and special sessions at SPUSA's regional and national events.

Nash, Audrey et. al (editors). "Science and Social Responsibility in the New Millennium Conference Proceedings." Washington, DC: Student Pugwash USA. Summer 2000.

Book

Science and Social Responsibility in the New Millennium: Conference Report. Washington, DC: Student Pugwash USA, June 1999.

Journal Article
Nash A et al. Science and Social Responsibility in the New Millenium. La Jolla, CA: Student Pugwash USA 1999. Book

Mind-full: A Brainsnack for Future Leaders with Ethical Appetites: Volume Two. Washington, DC: Student Pugwash USA, May 1999.

Journal Article

War-free world. mind-full a brainsnack Futur. leaders with ethical Appet. 2, 8 (1999).

Journal Article

JARVIK, Gail Pairitz - CSER RoRC Centralized Support Coordinating Center [U01 HG007307]

The Clinical Sequencing Exploratory Research (CSER) and Return of Results Consortium (RoRC) programs are designed to investigate critical questions about the application of genomic sequencing to clinical care of individual patients, from generation of genomic sequence data, to interpretation and translation of the data for the physician, to communication to the patient, including an examination of the ethical and psychosocial implications of bringing broad genomic data into the clinic. The goal of ELSI involvement in CSER is to support ELSI research required to responsibly apply personal genomic data to medical care, with a particular emphasis on the ethical, legal, and psychosocial implications of generating and returning genomic results, including returning incidental findings CSER website: https://www.genome.gov/27546194/clinical-sequencing-exploratory-researc…

Elizabeth V. Clarke, Jennifer L. Schneider, Frances Lynch, Tia L. Kauffman, Michael C. Leo, Ana G. Rosales, John F. Dickerson, Elizabeth Shuster, Benjamin S. Wilfond, Katrina A. B. Goddard . Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening. PLOS One, 2018. (Clarke EV, Schneider JL, Lynch F, Kauffman TL, Leo MC, Rosales AG, et al. (2018) Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening. PLoS ONE 13(7): e0200139. https://doi.org/10.1371/journal.pone.0200139) Journal Article

Creating a data resource: what will it take to build a medical information commons?

Journal Article
Bernhardt BA, Roche MI, Perry DL, Scollon SR, Tomlinson AN, Skinner D . Experiences with obtaining informed consent for genomic sequencing.. Am J Genet A, 167A (11):2635-46. 2015. [Wiley Online Library] Journal Article

Nelson, S. C. and S. M. Fullerton (2018). ""Bridge to the Literature"? Third-Party Genetic Interpretation Tools and the Views of Tool Developers." J Genet Couns 27(4): 770-781. [PubMed]

[PubMed]
Journal Article
Kauffman TL, Wilfond BS, Jarvik GP, Leo MC, Lynch FL, Reiss JA, Richards CS, McMullen C, Nickerson D, Dorschner MO, Goddard KA. . Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing.. Contemp Clin trials, 53 100-105. 2017. [PubMed] Journal Article

Genet Med. 2018 Apr;20(5):545-553. doi: 10.1038/gim.2017.137. Epub 2017 Aug 31.

Evans BJ . Economic regulation of next-generation sequencing.. J Law Med Ethics, 42 (S1):51-66. 2014. [Sage] Journal Article

Himes, P., Kauffman, T. L., Muessig, K. R., Amendola, L. M., Berg, J. S., Dorschner, M. O., . . . Goddard, K. A. B. (2017). Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. Genet Med, 19(7), 803-808. doi:10.1038/gim.2016.198

[PubMed]
Journal Article

Tan, N., Amendola, L. M., O'Daniel, J. M., Burt, A., Horike-Pyne, M. J., Boshe, L., . . . Jarvik, G. P. (2017). Is "incidental finding" the best term?: a study of patients' preferences. Genet Med, 19(2), 176-181. doi:10.1038/gim.2016.96

[PubMed]
Journal Article
Kraft SA1, McMullen CK, Porter KM, Kauffman TL, Davis JV, Schneider JL, Goddard KAB, Wilfond BS . Patient perspectives on the use of categories of conditions for decision making about genomic carrier screening results. Am J Med Genet A., 2018. [PubMed] (Am J Med Genet A. 2018 Feb;176(2):376-385. doi: 10.1002/ajmg.a.38583. Epub 2017 Dec 18.) Journal Article
Wilfond BS, Kauffman TL, Jarvik GP, Reiss JA, Richards CS5, McMullen C, Gilmore M, Himes P, Kraft SA, Porter KM, Schneider JL, Punj S, Leo MC, Dickerson JF, Lynch FL, Clarke E, Rope AF, Lutz K, Goddard KAB. . Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. Genet Med, 2018. [PubMed] (Genet Med. 2018 Oct;20(10):1186-1195. doi: 10.1038/gim.2017.243. Epub 2018 Feb 1.) Journal Article
Wilfond BS, Kauffman TL, Jarvik GP, Reiss JA, Richards CS, McMullen C, Gilmore M, Himes P, Kraft SA, Porter KM, Schneider JL, Punj S, Leo MC, Dickerson JF, Lynch FL, Clarke E, Rope AF, Lutz K, Goddard KAB. . Lessons Learned From A Study Of Genomics-Based Carrier Screening For Reproductive Decision Making. Health Aff (Millwood), 2017. [PubMed] (Health Aff (Millwood). 2018 May;37(5):809-816. doi: 10.1377/hlthaff.2017.1578.) Journal Article

JAVITT, Gail - Assessing the Impact of DTC Genetic Testing to Inform Policy Development [R21 HG004865]

This application proposes to assess the societal impact of genetic tests offered directly to consumers (DTC) and to develop policy options for DTC oversight that will balance the benefits of promoting availability of tests that can have a positive impact on public health and preventing harm to the public as a result of misleading claims, inappropriate tests, or inaccurate test results. DTC genetic testing challenges the traditional means of genetic test delivery. Some argue that genetic testing should take place only in the context of a health care provider, and that DTC genetic testing may harm consumers through inappropriate test selection, lack of counseling, and improper test interpretation. Others argue that DTC genetic testing may increase consumer awareness of, and access to, tests that can help them improve their health and make beneficial treatment and lifestyle decisions. Little is known about the legal or business landscape for genetic testing or its likely impact of DTC genetic testing on consumer behavior. Supporting research to ensure the effective and appropriate translation of genetics research to the public is a cornerstone of the ELSI program. The success of the Human Genome Project has led to the development of genetic tests for more than 1,200 diseases. A growing number of these tests are being offered DTC and there are few regulatory barriers to market entry. Therefore, we may expect to see significant growth of DTC genetic testing in the near future. The National Human Genome Research Institute has raised several significant research questions about DTC genetic testing. This project will provide the data needed to begin to answer some of these questions. It will develop a comprehensive landscape analysis of the DTC environment. It will evaluate claims for specific tests offered DTC and compare these claims to evidence of validity and utility in scientific literature. It will assess public awareness and attitudes regarding DTC genetic testing services and the experiences of consumers who have used two different DTC tests. Finally, it will develop policy options for oversight of DTC genetic testing. In all of these activities, the GPPC will serve as an expert resource for policymakers, the media and the public about DTC genetic testing. PUBLIC HEALTH REVELANCE STATEMENT This project is directly relevant to the health of the U.S. public. Advances in genomics have significant potential to benefit public health, but only if the public makes informed choices about whether to obtain genetic testing and what actions to take based on test results. The recent growth in direct-to-consumer (DTC) genetic testing presents questions, concerns, and opportunities, but little is known about its impact. Achieving the specific aims proposed of this project will provide the data and analysis needed for informed policy development for DTC genetic testing and important insights that can contribute to ensuring effective translation of discoveries in genetic research so as to benefit the public's health.

Aronson JD . The Strengths and Limitations of South Africa's Search for Apartheid-Era Missing Persons. Int J Transit Justice, 5 (2):262-81. 2011. [Full Text] Journal Article

JAYARATNE, Toby - Beliefs among Whites and African-Americans about Genetic Causes for Gender, Class and Race Differences: Social-Political Educational Implications [R01 HG001881]

This study will examine how the public conceptualizes human genetic mechanisms and interprets and uses this information. The major goals of this study are to 1) document the general character of the public's beliefs about how genes effect human traits, 2) investigate their use in explaining perceived differences between individuals and between gender, class and racial groups, and 3) explore the association between these beliefs and social-political attitudes. Three telephone surveys will be conducted with African American and white, female and male adult respondents from a range of socioeconomic levels. Two of these interviews will involve the collection of qualitative information from 40 respondents (each) and one structured interview will be conducted with 1,200 respondents, nationally sampled. Findings from this study will 1) give guidance to those of genetic counseling and education so they may better understand the public's conceptions of genetic mechanisms, 2) increase our knowledge about the role genetic explanations may play in gender, class and racial antagonism and stereotyping, and 3) inform those in the field of human genetics about the social and ethical implications of their work.

Jayaratne, T.E., Ybarra, O., Sheldon, J.P., Brown, T.N., Feldbaum, M., Pfeffer, C.A., Petty, E.M. "White Americans' Genetic Lay Theories of Race Differences and Sexual Orientation: Their Relationship with Prejudice toward Blacks, and Gay Men and Lesbians." Group Processes & Intergroup Relations. 2006; 9(1): 77-94.

[PubMed]
Journal Article

Cole ER, Jayaratne TE, Cecchi LA, Feldbaum MB, Petty EM. Vive La Difference? Genetic Explanations for Perceived Gender Differences in Nurturance. Sex Roles Springer Science. 57(3-4):211-22. 2007.

[Full Text]
Journal Article

Sheldon, J. P., Pfeffer, C. A., Jayaratne, T. E., Feldbaum, M. & Petty, E. M. Beliefs about the etiology of homosexuality and about the ramifications of discovering its possible genetic origin. J. Homosex. 52, 111–50 (2007).

[Taylor & Francis Online]
Journal Article
Brown TN, Akiyama MK, White IK, Jayaratne TE, Anderson ES . Differentiating Contemporary Racial Prejudice from Old-Fashioned Racial Prejudice. Race Soc Probl, 1 (2):97-110. 2009. [PubMed] Journal Article
Christensen KD, Jayaratne TE, Roberts JS, Kardia SL, Petty EM . Understandings of basic genetics in the United States: results from a national survey of black and white men and women.. Public Health Genomics, 13 (7-8):467-76. 2010. [PubMed] Journal Article

Suhay, E. & Jayaratne, T. E. Does Biology Justify Ideology? The Politics of Genetic Attribution. Public Opin. Q. 77, 497–521 (2012).

[Oxford Journals]
Journal Article

Sheldon, J. P., Epstein Jayaratne, T., Feldbaum, M. B., DiNardo, C. D. & Petty, E. M. Applications and implications of advances in human genetics: perspectives from a group of Black Americans. Community Genet. 10, 82–92 (2007).

[PubMed]
Journal Article

Lanie, A. D. et al. Exploring the public understanding of basic genetic concepts. J. Genet. Couns. 13, 305–20 (2004).

[PubMed]
Journal Article

Jayaratne, T. E. et al. The perennial debate: Nature, nurture, or choice? Black and White Americans’ explanations for individual differences. Rev. Gen. Psychol. 13, 24–33 (2009).

[PubMed]
Journal Article

JOFFE, Steven - Returning Individual Genetic Results to Participants in Cohort Studies [R01 HG005083]

Methodological advances now permit the use of genome-wide association studies (GWAS) to discover novel genotype-phenotype associations. GWAS offer a powerful tool for identifying genetic contributions to both common and rare diseases. At the same time, GWAS raise profound and challenging ethical questions. The most pressing questions derive from the likelihood that GWAS will uncover genetic information with the potential to be clinically meaningful to individual participants. As a result, investigators will inevitably face the question of whether individual genetic results from genome-wide scans should be disclosed to subjects. Commentators and ethics panels have addressed the question of whether genetic test results should be returned to research participants. Most policymakers advocate a cautious approach: disclosure should be limited to a narrow subset of results that meet stringent criteria related to magnitude of risk, severity of phenotype, and availability of prophylactic, therapeutic or reproductive interventions. Limited data regarding research participants' views, on the other hand, suggest a strong preference for disclosure of test results. However, because these data are based upon dichotomous responses to single questions, they do not address whether participants' views are sensitive to the factors identified by expert panels as salient to decisions about return of results. Without such information, it is impossible to know whether the gap between participants' views and policy guidance is as profound as the data suggest. The present proposal aims to bridge this gap through a factorial survey of 1800 members of the Jackson and Framingham Heart Studies, two influential cardiovascular cohort studies that conduct GWAS. Specifically, the proposed study will evaluate whether the criteria highlighted by policymakers are predictive of research participants' desires for this information. The study will also evaluate the relationships between attitudinal characteristics (e.g., views on and knowledge about genetics) and sociodemographic characteristics (e.g., age, education) and participants' desires for return of results. The findings will permit assessment of the extent to which there is concordance between the views of experts and those of research participants on this vexing topic. These data will help shape practice and policy regarding the return of individual results from genomic research.

Saylor KW, Ekunwe L, Antoine-LaVigne D, Sellers DE, McGraw S, Levy D, Splansky GL, Joffe S. . Attitudes Toward Genetics and Genetic Testing Among Participants in the Jackson and Framingham Heart Studies.. J Empir Res Hum Res Ethics, 14 (3):262-273. 2019. [] Journal Article

JOHNSTON, Josephine Marguerite - Goals and Practices for Next Generation Prenatal Testing [R01 HG008805]

Prenatal testing is evolving in two important ways: first, advances in genomic medicine mean that samples of fetal DNA obtained with invasive methods (such as amniocentesis) can be analyzed using microarray analysis or whole genome sequencing, revealing far more information about the fetus's genetic make-up than was previously possible; and second, new, non-invasive prenatal tests have been introduced that isolate fragments of fetal DNA circulating in a pregnant woman's blood, making possible safe, highly accurate genetic testing much earlier in pregnancy than was previously possible. Currently the range of genetic traits that can be picked up by the new non-invasive tests is small. But it is set to expand rapidly as the technology develops, and it may one day soon extend to whole genome analysis allowing detection of the full range of traits, including those associated with increases in risk for disease, adult-onset conditions, and non-disease traits. These two changes mark the beginning of the next-generation of prenatal testing, which has the potential to dramatically alter the experience and care of the 4 million women who give birth in the United States alone each year. Thereby, these remarkable technological developments raise pressing ethical, which this project will address. First, which traits should be tested for, nd how ought testing be conducted? Second, which policies should be altered to support the ethical use of next-generation prenatal tests, and in what ways should these policies be changed? And third, what future empirical research is needed to examine how the ethics recommendations made by this project play out in practice? To address these questions, The Hastings Center has recruited experts and representatives from a wide range of sectors critical to the wise and effective use of next- generation prenatal tests, but who have not yet been brought together. Importantly, leaders from the major relevant clinical societies have agreed to participate because they realize that this project's ethical analysis and recommendations will usefully inform their organizations' future clinical guidelines. The Work Group also includes members conducting empirical research on first and second-generation prenatal testing, and members representing patients. Together, with this Work Group, the Lead Investigators will produce analysis and recommendations for clinicians, researchers, policy makers, opinion leaders and the public. A draft of this analysis and recommendations will be presented to four focus groups of pregnant women and the partners of pregnant women for their feedback. The final analysis and recommendation will be disseminated to relevant stakeholders via scholarly publications, conference presentations, a public meeting, and a project website.

Johnston J, Farrell RM, Parens E. . Supporting Women's Autonomy in Prenatal Testing.. N Engl J Med., 377 (6):505-507. 2017. [] Journal Article

JONSEN, Albert - A Paradigm Approach to Ethical Problems in Genetics [R01 HG000477]

This project utilizes a method of ethical analysis described as 'paradigm analysis' to develop a comprehensive and systematic framework for ethical issues raised by genomic information in clinical genetics. Several diseases with genetic bases will be used to group specific sets of ethical issues and a method for ethical analysis will be devised. The project will have three phases: 1) a working group from ethics, clinical genetics, and scientific genetics, drawing from the literature on genetic ethics, clinical experience, and prospective scientific developments, will meet on a regular basis to select and describe the paradigms; 2) the chosen paradigms will be tested for adequacy and accuracy against the records of patients in the genetics clinics of the University of Washington; and 3) the paradigms will be refashioned in response to record derived data and a report explaining the paradigmatic method will be prepared and distributed throughout the genetics and ethics community. Utility of the method for a computerized data base will be explored.

Jonsen, A.R. "Genetic Testing, Individual Rights, and the Common Good." In: Duties to Others, eds. C. Campbell and A. Lustig. Boston: Kluwer Academic, 1994. 319p.

Book Chapter

Callahan, T.C.; S.J. Durfy; and A.R. Jonsen. "Ethical Reasoning in Clinical Genetics: A Survey of Cases and Methods." Journal of Clinical Ethics. Fall 1995: 6(3); 248-253.

Journal Article

Jonsen, A.R. "The Impact of Mapping the Human Genome on the Patient Physician Relationship." In: The Human Genome Project and The Future of Health Care, eds. T.H. Murray, M. Rothstein, and R. Murray. Bloomington: Indiana University Press, 1996. 248p.

Book Chapter

Durfy, S.J. "Ethics and the Human Genome Project." Archives of Pathology and Laboratory Medicine. May 1993: 117(5); 466-469.

Journal Article

JUENGST, Eric - Center for Genetic Research, Ethics, and Law (CGREAL) [P50 HG003390]

The mission of the proposed Center for Genetics Research Ethics and Law (CGREL) is to foster sustained interdisciplinary research on the ethical, legal, and social issues involved in the design and conduct of human genetics research with individuals, families, communities, and populations. CWRU already hosts a variety of research efforts relevant to the CGREL's theme. The CGREL will integrate these efforts to launch new research collaborations and provide the resource structure necessary for their application to high priority genetics research policy questions. The basic architecture of the CGREL consists of six overlapping research groups, six research resource cores, and a research training program. The research collaborations generated by the CGREL will be harnessed to pursue four Center-wide research aims, which we believe reflect the highest priority needs in genetic research ethics and policymaking: —> To improve our understanding of the relationship between human genetics research and the humans it seeks to benefit by elucidating the cultural values and beliefs that influence different people's reactions to and experience of genetics research participation. —> To improve our understanding of the relationship between human genetics research and the human benefits it promises by elucidating the influence of translational incentives, ranging from commercial prospects to benefit-sharing agreements, on the design and conduct of basic genetics research. —> To anticipate the research ethics and science policy issues raised by new advances in genetics research by analyzing the confluence of human variation research, computational genomics, sequencing technologies, and gene transfer techniques through the lenses of contemporary research regulations and norms. —> To harness ongoing scholarship on genetics research ethics for practical application by providing evidence-based policy options for use by the scientific community, institutional review boards, and national research regulatory bodies in seeking to improve participant protections in the design and conduct of human genetic research.

Juengst, E.: Population-based Genetic Research and Screening: Conceptual and Ethical Issues. In The Handbook of Bioethics. B. Steinbook(ed.). Oxford, Oxford University Press: 471-491. 2006.

Book Chapter

Marshall, P.: Ethical Issues in Research Design and Informed Consent in Resource Poor Countries. World Health Organization. 2006.

Book

Berg, J. W. Of Elephants and Embryos: A Proposed Framework for Legal Personhood. Hast. Law J. 59, 369 (2007).

[Selected Works]
Journal Article

Juengst, E. T. & Goldenberg, A. in Oxford Textb. Clin. Res. Ethics (Emanuel, E. J. et al.) 298–314 (Oxford University Press, 2008).

Book Chapter

Juengst, E. "Altering the human species? Misplaced essentialism in science policy," In Rasko, J., O'Sullivan, G. and Ankeny, R. (eds.), The Ethics of Inheritable Genetic Modification: A Dividing Line? Cambridge: Cambridge University Press. pp. 149-58. 2006

Book Chapter

Macklin, R., Juengst, E.: Genetic and reproductive technologies. In The Encyclopedia of Philosophy, 2nd Edition. Thompson Gale. 2006.

Book Chapter

Workman, M. L. & Winkelman, C. Genetic influences in common respiratory disorders. Crit. Care Nurs. Clin. North Am. 20, 171–89, vi (2008).

[PubMed]
Journal Article

Davis, D. S. The changing face of “misidentified paternity”. J. Med. Philos. 32, 359–73 (2007).

[PubMed]
Journal Article

Juengst, E., Ponsaran, R. "Normal aging, disease prevention and medical ethics." Public Policy and Aging Report 2004: 14-18.

Journal Article

Juengst, E. T. in Ethics, Genet. Futur. Sport Implic. Genet. Modif. Sel. (Murray, T. H.) 175–204 (Georgetown University Press, 2009).

Book Chapter

Juengst E, Grankvist H. Ethical Issues in Human Gene Transfer: A Historical Overview. In Principles of Health Care Ethics. ed. R Ashcroft. John Wiley and Sons. pp. 789-796. 2007.

Book Chapter

Dressler L, Juengst E. Thresholds and boundaries in the disclosure of individual genetic research results. American Journal of Bioethics, 6:18-20. 2006.

[PubMed]
Journal Article

Marshall P. Ethical Issues in Research Design and Informed Consent to Biomedical and Social Research in Resource Poor Settings. Geneva: World Health Organization, Special Topics in Social, Economic, and Behavioral Research Series of Programme for Research and Training in Tropical Diseases (TDR), 2007.

Book Chapter

Davis D. A Thoughtful Look at Disability. Hastings Center Report, 54-55(2). 2007.

Journal Article

Dressler L. Control and Use of Banked Human Specimens in Research. Biospecimen
Ownership Counterpoint. Journal of Cancer Epidemiology, Prevention and Biomarkers, 16(2):190-191. 2007.

[PubMed]
Journal Article

Juengst ET. "FACE facts: Why human genetics will always provoke bioethics." J Law Med Ethics 2004; 32(2):267-75, 191.

[PubMed]
Journal Article

Liu, Y. I., Wise, P. H. & Butte, A. J. The “etiome”: identification and clustering of human disease etiological factors. BMC Bioinformatics 10 Suppl 2, S14 (2009).

[PubMed Central]
Journal Article

Hoffman S. "In There a Place for 'Race' as a Legal Concept?" Arizona State Law Journal. 2004; 36(4): 1093-1159.

Journal Article

Davis, D.S. "Genetic Research & Communal Narratives." Hastings Center Report. 2004; 34(4):40-49.

[PubMed]
Journal Article

Mehlman, M.J. "Genetic Enhancement: Plan Now to Act Later." Kennedy Institute of Ethics Journal. 2005; 15(1): 77-82.

[PubMed]
Journal Article

Settersten, R. A., Flatt, M. A. & Ponsaran, R. S. From the Lab to the Front Line: How Individual Biogerontologists Navigate their Contested Field. J. Aging Stud. 22, 304–312 (2008).

[PubMed]
Journal Article

Leppert M, Matsuda I, et al. Community Engagement, Public Consultation, and Informed Consent in the International HapMap Project. Community Genetics, 10(3):186-198. 2007.

[PubMed]
Journal Article

Winkelman C, Higgins PA, Chen Y-J K, Levin A. Cytokines in chronically critically ill patients after activity and rest. Biologic Research for Nursing, 8(4):261-71. 2007.

[PubMed]
Journal Article

Binstock, R. H. & Fishman, J. R. in SAGE Handb. Soc. Gerontol. (Dannefer, D. & Phillipson, C.) 472–482 (Sage Publications, Inc., 2010).

Book Chapter

Fishman, J. R., Binstock, R. H. & Lambrix, M. A. Anti-aging science: The emergence, maintenance, and enhancement of a discipline. J. Aging Stud. 22, 295–303 (2008).

[Science Direct]
Journal Article

Davis D. Genetic Testing and Tort Actions. In Genetic Testing: Care, Consent, and Liability. N.F. Sharpe and R.F, eds. Carter. Hoboken, N.J. , Wiley-Liss: 107-127. 2006.

Book Chapter

JUENGST, Eric - Anticipating Enhancement: Ethical, Legal and Social Issues [R01 HG001446]

This project will delineate the major ethical, legal and social issues accompanying the use of genomic information to enhance normal traits in individuals and families, and to identify the precedents that best illuminate those issues for policy-making purposes. The study will use a traditional policy analysis approach to generate specific positions on five issues of genetic enhancement policy issues: 1) Do the human subjects of clinical research on genetic enhancement interventions require special protections? 2) How should the professionally acceptable limits of genomic services be drawn? 3) What constitutes fair access to genetic enhancement services? 4) How should genetic enhancement technologies be regulated? 5) How should support for research towards germ-line gene therapy be affected by genomics' genetic enhancement capacities?

Juengst, E. T. in Encycl. Ethical, Leg. Polit. Issues Biotechnol. (Murray, T. H. & Mehlman, M. J.) (John Wiley and Sons, 2000).

Book Chapter

Juengst, E.T. and E. Parens. "Germ-line Dancing: Definitional Considerations for Science Policy Makers." In Points to Consider Regarding Inherited Genetic Modifications in Human Beings, A. Chapman and M. Frankel (eds.) Washington, DC: AAAS. 2003.

Book Chapter

Juengst, E.T. and L. Walters. "Ethical Issues in Human Gene Transfer Research." p. 691-712, in The Development of Human Gene Therapy, T. Friedman, Ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999.

Book Chapter

Juengst, E.T. "What Does Enhancement Mean?" p. 29-47, in Enhancing Human Traits: Ethical and Social Implications, E. Parens, Ed. Washington, DC: Georgetown University Press, 1998.

Book Chapter

Juengst, E.T. "Anticipating Enhancement: A Conceptual and Ethical Challenge for Gene Therapy Regulation." p.97-109, in Gene Therapy and Ethics, A. Nordgren, Ed. Uppsala: Acta Universitatis Upsaliensis, 1999.

Book Chapter

JUENGST, Eric - Enhancement: Professional Ethical and Public Policy Issues [R01 HG001446]

In their previous project, these investigators examined the ethical and legal issues raised by the prospect of using the products of human genome research for enhancement purposes. This work identified three critical challenges to the development of social poicy in this area. First, most interventions that can be used for enhancement are likely to be initially developed and approved for therapeutic use. However, once so approved, the current regulatory structure provides no adequate means of managing the 'off-label' use of such interventions for enhancement purposes by clinicians and their clients. Second, any enhancement interventions performed on pre-implantation embryos are likely to be undertaken in the largely unregulated context of clinical reproductive biology and infertility medicine. While the previous project has allowed the investigators to outline the considerations relevant to professional ethics in this area, it is still not clear how those standards would be best enforced. Finally, the availability of either pre-implantation or post-implantation genetic enhancement interventions will also depend on policies regarding access to these interventions outside the boundaries of the U.S. This new project will undertake a close-grained analysis of these three problems as they challenge the management of genetic enhancement technologies, and will develop specific policy recommendations for public policy makers that would allow the issues to be addressed within the framework of considerations set out in the previous project. The project's methods will be primarily analytic and discursive: they will be critiquing, constructing, and proposing policy positions on the basis of literature about the closest precedents for each of these problems by continuing the regimen of regular research meetings and collaborative writing that has propelled their work to date.

Juengst E.T. "Growing pains: Bioethical perspectives on growth hormone replacement research" J Anti-Aging Med, 5(1): 73-79 Spring 2002

Journal Article

JUENGST, Eric - Enhancement Ethics and the Molecular Genetics of Aging [R01 AG020916]

Advances in the molecular genetics of cellular aging raise the prospect of intervening in the human aging process to dramatically extend the human life span. The development of such interventions would confront society with the challenge of interpreting, using and regulating the ultimate genetic enhancement technology: a technology that could allow us to change a basic constant of human life at the cellular level. This project is designed to combine the work of two ongoing research programs to begin to address these challenges. The first is the research that Eric Juengst, Maxwell Mehlman and Thomas Murray have been conducting on the ethical and public policy challenges that are posed generically by genetic enhancement technologies. The framework for ethical analysis and public policy development generated by that research would be applied here to the case of anti-aging interventions, both as a test of the framework and to see what it yields in this case. The second resource is the work of the other co-investigators, Stephen Post, Peter Whitehouse and Robert Binstock, on the clinical and social meanings of the human aging process. That research will be used to identify the issues to analyze in this project, by providing the landscape of contemporary social practices, values and beliefs that radical life extensions could challenge. Collaboratively, the two groups will seek to anticipate the issues that anti-aging interventions could raise for three constituencies: the individuals and families that might use them, the health professionals that might provide them, and the public-policy makers that will shape the context in which they might become available. The project's methods will be analytic and discursive: the investigators will be critiquing, constructing and proposing arguments on the basis of existing information and previous work, through a regimen of regular research meetings and collaborative writing. This work will be overseen by an expert group of advisors; Carol Donley, Co-director, Center for Literature, Medicine and the Health Profession at Hiram College; Michael Fossel, Editor, Journal of Anti-Aging Medicine; Linda George, Associate Director, Center for the Study of Aging and Human Development, Duke University; and Thomas Murray, President, The Hastings Center.

Whitehouse, P.J, Juengst, E.T. "Antiaging medicine and mild cognitive impairment: Practice and policy issues for geriatrics." J. Am. Geriatr. Soc.. 2005; 53(8): 1417-1422.

[PubMed]
Journal Article

Juengst, E.T., Binstock, R.H., Mehlman, M., et al. "Biogerontology, 'anti-aging medicine,' and the challenges of human enhancement." Hastings Center Report. 2003; 33(4):21-30

[PubMed]
Journal Article

Juengst, E.T.; Binstock, R.H.; Mehlman, M.J., et al. "Aging- Antiaging research and the need for public dialogue." Science. 2003. 299(5611): 1323-1323.

[PubMed]
Journal Article

Binstock, R. H., et al. (2006). "Boundaries and labels: anti-aging medicine and science." Rejuvenation Res 9(4): 433-435. [PubMed]

[PubMed]
Journal Article

Binstock, R., Fishman, J., Juengst, E.: Anti-aging medicine and science: Social implications. 6th Edition. Binstock, R., George, L.K. and Cutler, S. J. Handbook of Aging and the Social Sciences. Academic Press. 2006.

Book Chapter

Mehlman, M.J., Binstock, R.H., Juengst, E.T., et al. "Anti-aging medicine: Can consumers be better protected?" Gerentologist 2004. 44(3): 304-310.

[PubMed]
Journal Article
Allyse M, Karkazis K, Lee S et al. Informational risk, institutional review, and autonomy in the proposed changes to the common rule. IRB, 34 (3):17-9. 2012. [PubMed] Journal Article

JUENGST, Eric - Anticipating Personal Genomic Medicine: Impact and Implications [R01 HG005277]

"Personalized genomic medicine" (PGM) is being promoted as a "new paradigm for health care" and a major goal for translational genomic research (TGR). In addition to overcoming TGR's remaining scientific hurdles, achieving that goal will involve addressing a number of ethical, legal, and social challenges. Some of those challenges reflect the ways that different social policies and health care economies will complicate TGR's ability to realize PGM as a viable health care paradigm. But other challenges might emerge from the goal itself, depending upon how PGM is interpreted by those who shape it as a social practice. This project explores this suggestion by documenting how PGM and its most attractive virtues are interpreted by those involved in defining them for TGR and society, and the challenges and choices they are encountering in the process. PGM is a goal that unites a wide array of biomedical initiatives, from medical sequencing, gene expression, and pharmacogenomics research to public health, clinical, and commercial services. Its promissory virtues are precision diagnosis and risk prediction, individualized therapy, prevention, health promotion, and patient empowerment. Different proponents of PGM interpret and rank these promises differently, with different implications for the realization of PGM as a health care paradigm. We focus on four sets of interpreters that will have particularly important roles in shaping the way PGM emerges as a social practice: (1) the scientists, research sponsors, companies, and policy organizations that promote PGM as a biomedical paradigm; (2) the journals, public review bodies and educational institutions that mediate the implementation of this paradigm; (3) the health care institutions and professionals that pioneer the paradigm by providing PGM services in practice; (4) the patient-based organizations that increasingly help shape its public reception. Our empirical studies of the views of these social co-producers of PGM will then be used to generate an analytic map of their different visions, designed to draw out their ethical, legal, and social implications for TGR and health policy. The "translational pipeline" of genomic research will have many branches towards its distal end. This project is designed to anticipate the directional choices that these branches will require, so that the PGM that TGR finally delivers into the complicated plumbing of our society is as clean and safe as possible. PUBLIC HEALTH RELEVANCE: A major goal of genomic research is to develop health care tools that can achieve more precise diagnoses and risk predictions, individualized therapy, prevention, health promotion, and greater patient empowerment. The proponents of these advances call their goal "personalized genomic medicine." But many different parties are involved in shaping this vision for health care, and their different interpretations of its virtues carry different ethical, social, and legal implications. The purpose of this project is to study how some of the most influential parties who are promoting, implementing, providing, and using "personalized genomic medicine" understand its promises and potential pitfalls. This understanding will allow us to define the policy choices that lie ahead for researchers, health care providers, and the public as translational genomic research moves closer to its goal.

Dressler LG. Control and use of banked human specimens in research. Biospecimen ownership. Counterpoint. Journal of Cancer Epidemiology, Prevention and Biomarkers, 16(2):190-191. 2007.

[PubMed]
Journal Article

Cadigan, R. J. et al. Neglected ethical issues in biobank management: Results from a U.S. study. Life Sci. Soc. policy 9, 1 (2013).

[PMC]
Journal Article

Displaying 1201 - 1300 of 1985 publications.

Last updated: January 24, 2019